Merck Sharp + Dohme Corp.

Ivory D Hills

Craig Alan Coburn

Samuel L Graham

Melissa S Egbertson

Shaun R Stauffer

Shawn J Stachel

Philippe G Nantermet

Michelle R Machacek

Hemaka Anthony Rajapakse

Keith P Moore

Pablo De Leon

Ashley Nomland

Adam W Johnson

Hong Zhu

Pablo DeLeon

Adam Wayne Johnson

Hemaka A Rajapakse

The present invention is directed to quinolinone compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

Quinolinone PDE2 inhibitors

The present invention is directed to 2-aminoimidazole compounds of formula (I) which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.

2-aminoimidazole beta-secretase inhibitors for the treatment of alzheimer's disease

The present invention is directed to spiropiperidine compounds of formula (I) which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.

Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease

Growing community of inventors

Harleysville, PA, United States of America

Ivory D Hills